Mammoplasty Clinical Trial
Official title:
Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy
Verified date | February 2019 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Breast implants, either cosmetic or reconstructive, are among the most common procedures performed by plastic surgeons. Bacterial infections or biofilms are implicated in the majority of breast implant complications including infection requiring explantation, capsular contracture (CC), and/or breast-implant associated anaplastic large cell lymphoma (BIA-ALCL). The research team, which has already extensively characterized bacterial pathogenesis in the urinary tract and designed non-antibiotic therapeutics to reduce the incidence of catheter-associated urinary tract infections (CAUTIs), and proposal will study bacteria-breast implant interactions and explore further the impact of the breast microbiome. The proposed research provides a greater understanding of which bacteria can colonize breast implants, their source, and how effective antibiotic pocket irrigation is at eliminating them, and begins to examine the mechanisms by which bacteria bind and colonize the implant surface. These insights will set the groundwork for developing new therapeutic agents that can disrupt the binding of certain bacteria to breast implants. Strategies that minimize problems bacteria can cause, while avoiding antibiotics, will reduce bacteria-related implant complications, limit antibiotic-related side effects, and reduce bacterial resistance.
Status | Completed |
Enrollment | 19 |
Est. completion date | September 26, 2018 |
Est. primary completion date | September 26, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Female - Between 18 and 75 years of age, inclusive - Undergoing bilateral mastectomy reconstruction with tissue expanders (ipsilateral therapeutic/contralateral prophylactic) planned to be exchanged for breast implants - Able to understand and willing to sign an IRB-approved written informed consent document Exclusion Criteria: - Male |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine | The Plastic Surgery Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of tissue expander(s) removed due to infection | The bulk of analyses will be to study bacterial biofilm formation on the explanted breast tissue, skin/scar, drain, acellular dermal matrix, tissue expander, and capsule. | Up to 1 year | |
Primary | Number of tissue expander(s) removed due to patient preference | Up to 1 year | ||
Secondary | Duration of implantation | Up to 1 year | ||
Secondary | Duration the drain was in | Up to 1 year | ||
Secondary | Incidence of development of an infection or a wound | Up to 1 year | ||
Secondary | Incidence of capsular contracture | Up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03744013 -
A Post Market Prospective Study of FORTIVA® 1mm Porcine Dermis
|
N/A | |
Completed |
NCT00505557 -
Dual-Plane Breast Augmentation: Axillary Approach With Assistant of Endoscope
|
Phase 1 | |
Active, not recruiting |
NCT06079086 -
Evaluation of the Clinical Evolution of Breast Increase Using Prostheses
|
N/A | |
Recruiting |
NCT04307355 -
Continuous Diffusion of Oxygen Treatment for Incision Wounds
|
Phase 1/Phase 2 | |
Completed |
NCT04331080 -
A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery
|
Phase 2/Phase 3 | |
Completed |
NCT01582490 -
Study of EXPAREL in Patients Undergoing Breast Augmentation
|
Phase 4 |